AES-135
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-114483-1MG | 1 mg | 254,00 | Add | |
| HY-114483-5MG | 5 mg | 521,00 | Add | |
| HY-114483-1ML | 10mM/1mL | 786,00 | Add | |
| HY-114483-10MG | 10 mg | 875,00 | Add | |
| HY-114483-25MG | 25 mg | 1'723,00 | Add | |
| HY-114483-50MG | 50 mg | 2'801,00 | Add | |
| HY-114483-100MG | 100 mg | 4'320,00 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC50s ranging from 190-1100 nM[1].
| Category | Biochemicals |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, Cell Cycle/DNA Damage,Epigenetics |
| Format | Solubility: DMSO : 100 mg/mL (ultrasonic) |
| Grade | Clinical information: No Development Reported |
| Purity | 98.21% |
| Molecular Formula | C33H29F6N3O5S |
| Molecular Weight | 693.66 |
| CAS-Number | 2361659-61-0 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
